NTHI -
NeOnc Technologies Holdings, Inc. Common Stock
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 5.95 -0.09 (-1.51%) |
--- |
--- |
0.0 (0.0%) |
--- |
-0.09 (-1.51%) |
--- |
--- |
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
Earnings & Ratios
- Basic EPS:
- -0.3
- Diluted EPS:
- -0.3
- Basic P/E:
- -19.5333
- Diluted P/E:
- -19.5333
- RSI(14) 1m:
- 100.0
- VWAP:
- 5.86
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors
Dec 01, 2025 14:00
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
Nov 07, 2025 14:00
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
Oct 09, 2025 13:00
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
Sep 29, 2025 13:00
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
Aug 25, 2025 13:00
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
Aug 07, 2025 13:00
NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors
Jul 30, 2025 13:00
CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.
Jul 23, 2025 14:53
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
Jul 08, 2025 13:00